Overview

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

Status:
Completed
Trial end date:
2017-08-03
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Ixekizumab